Lorvotuzumab mertansine: Phase I/II started

ImmunoGen began a dose-escalation, international Phase I/II trial to compare weekly IMGN901 given for the first 2 weeks in a 3-week cycle plus standard of care (SOC; carboplatin and etoposide) vs. SOC...